- Conditions
- Cervical Intraepithelial Neoplasia
- Interventions
- EM-1421
- Drug
- Lead sponsor
- Erimos Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Not listed
- Lead sponsor
- STI-Medical Systems
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Honolulu, Hawaii
- Conditions
- Metrorrhagia, Pelvic Pain, Menorrhagia, Leiomyoma
- Interventions
- Myfembree Oral Product
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 6
- States / cities
- Chicago, Illinois • Flossmoor, Illinois • Orland Park, Illinois + 1 more
- Conditions
- Recurrent Endometrial Carcinoma, Recurrent Ovarian Carcinoma, ARID1A Gene Mutation
- Interventions
- Bevacizumab, Niraparib
- Drug
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 2
- States / cities
- Oklahoma City, Oklahoma • Charlottesville, Virginia
- Conditions
- Precancerous Condition, Stage 0 Cervical Cancer
- Interventions
- Cervical Papanicolaou Test, Conization, Laboratory Biomarker Analysis
- Other · Procedure
- Lead sponsor
- Gynecologic Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 684 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1998
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Uterine Cervical Neoplasms
- Interventions
- Bintrafusp alfa
- Drug
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 11
- States / cities
- Fayetteville, Arkansas • Little Rock, Arkansas • Stanford, California + 8 more
- Conditions
- Cancer of Head and Neck, Cancer of Cervix, Cancer of Anus
- Interventions
- DPX-E7 vaccine, Cyclophosphamide
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Cancer
- Interventions
- recombinant interleukin-12
- Biological
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 18 Years and older · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2005
- U.S. locations
- 9
- States / cities
- Boston, Massachusetts • Flemington, New Jersey • Hackensack, New Jersey + 6 more
- Conditions
- Advanced Solid Tumor, Locally Advanced Solid Tumor, Metastatic Solid Tumor, Platinum-resistant Ovarian Cancer, Post Anti-PD-1 Melanoma, 2L+ Cervical Cancer, Neoadjuvant Melanoma, Neoadjuvant Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Non-Small Cell Lung Cancer, Post Anti-PD-(L)1 Small Cell Lung Cancer, Third Line or Later (3L+) HER2+ Breast Cancer, Second or Third Line (2L/3L) Cervical Cancer, Third-line or Later (3L+) Platinum-resistant Ovarian Cancer (PROC)
- Interventions
- TransCon IL-2 β/γ, Pembrolizumab, Chemotherapy drug, TransCon TLR7/8 Agonist, Surgery, Trastuzumab, Trastuzumab emtansine (T-DM1)
- Drug · Procedure
- Lead sponsor
- Ascendis Pharma Oncology Division A/S
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2029
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Springfield, Illinois • Louisville, Kentucky + 10 more
- Conditions
- Bone Cancer, Brain Cancer, Colorectal Cancer, Esophagus Cancer, Lymphoma, Salivary Gland Cancer, Head and Neck Cancer, Liver Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Small Intestine Cancer, Stomach Cancer, Urinary Bladder Cancer, Anal Cancer, Blood Cancer, Breast Cancer, Cervical Cancer, Lung Cancer, Kidney Cancer, Penile Cancer, Skin Cancer, Testicular Cancer, Thyroid Cancer, Uterine Cancer, Vaginal Cancer, Vulvar Cancer
- Interventions
- Standard assistance, Enhanced assistance
- Other
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Uterine Fibroids, Heavy Menstrual Bleeding
- Interventions
- OBE2109, Placebo to match OBE2109, Placebo to match Add-back, Add-back
- Drug
- Lead sponsor
- ObsEva SA
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 116
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 93 more
- Conditions
- Cancer
- Interventions
- Oral lapatinib tablets or placebo tablets
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 20
- States / cities
- Denver, Colorado • Indianapolis, Indiana • Overland Park, Kansas + 17 more
- Conditions
- Cervical Cancer
- Interventions
- CHW Outreach and HPV Self-sampling, CHW Outreach
- Behavioral
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 601 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2015
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Endometrial Neoplasms
- Interventions
- Paclitaxel, Sapanisertib, MLN1117
- Drug
- Lead sponsor
- Millennium Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 21
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Greenbrae, California + 17 more
- Conditions
- Leiomyoma
- Interventions
- CDB-2914
- Drug
- Lead sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- NIH
- Eligibility
- 33 Years to 50 Years · Female only
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2015
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Head and Neck Cancer, Cervical Cancer, Non Small Cell Lung Cancer, HPV16 Related Cancers, Sarcoma, Uveal Melanoma, NUT Carcinoma
- Interventions
- Tumor and HLA Profiling
- Diagnostic Test
- Lead sponsor
- TScan Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • San Diego, California • New Haven, Connecticut + 17 more
- Conditions
- Cervical Cancer, Behavior
- Interventions
- Care Group Cervical Cancer Screening Education Curriculum
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 30 Years to 59 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Endometrial Cancer
- Interventions
- Sonohysterography
- Procedure
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Fallopian Tube Cancer, Peritoneal Cancer
- Interventions
- temsirolimus, cediranib
- Drug
- Lead sponsor
- Susana M. Campos, MD
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2021
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Cervical Adenocarcinoma, Cervical Squamous Cell Carcinoma, Human Papillomavirus Infection, Recurrent Cervical Carcinoma, Stage IVA Cervical Cancer AJCC v6 and v7, Stage IVB Cervical Cancer AJCC v6 and v7
- Interventions
- Ipilimumab, Laboratory Biomarker Analysis
- Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2021
- U.S. locations
- 5
- States / cities
- Duarte, California • Sacramento, California • South Pasadena, California + 2 more
- Conditions
- Refractory Endometrial Adenocarcinoma, Refractory Endometrial Carcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma
- Interventions
- Extended-release Onapristone, Anastrozole, Quality-of-Life Assessment, Questionnaire Administration, Estrogen Receptor Positive (Positive Estrogen Receptor; ESR Positive; ESR1 Positive; ER Positive; Estrogen Receptor Alpha Positive), Progesterone Receptor Positive ( PGR Positive; PR Positive)
- Drug · Other · Diagnostic Test
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 2
- States / cities
- Abington, Pennsylvania • Philadelphia, Pennsylvania
- Conditions
- Endometrial Cancer
- Interventions
- Carboplatin, Paclitaxel, bevacizumab
- Drug
- Lead sponsor
- David O'Malley
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2017
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- KRAS G12D Mutation, Advanced Solid Cancer
- Interventions
- ARV-806
- Drug
- Lead sponsor
- Arvinas Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 76 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more
- Conditions
- Anxiety Disorder, Worry, Uncertainty, Sleep Disorders, Insomnia, Fatigue, Pain, Depression, Cognitive-behavioral Therapy, Psychological Intervention, Esophageal Cancer, Pancreatic Cancer, Leukemia, Lung Cancer, Multiple Myeloma, Ovarian Neoplasm, Stage III or IV Cervical or Uterine Cancer, Stage IIIB, IIIC, or IV Breast Cancer, Glioblastoma Multiforme, Relapsed Lymphoma, Stage III or IV Colorectal Cancer, Stage IIIC or IV Melanoma
- Interventions
- Cognitive-behavioral therapy for worry, uncertainty & insomnia
- Behavioral
- Lead sponsor
- Ohio State University Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Columbus, Ohio